PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.

ABSTRACT:

Background

Inhibitors of poly(ADP-ribose) polymerase (PARPi, e.g. olaparib) induce a tumour-suppressive chemokine release via STING in homologous recombination deficient (HRD) and proficient (HRP) cancers.

Methods

Dose-dependent effects of olaparib on HRD (ID8-Brca2^(-/-)) and HRP (ID8) ovarian cancer cell proliferation and chemokine release. Survival of immunocompetent and immunocompromised ID8 mouse models treated with different olaparib doses. Inhibition and overexpression of the chemokine-inactivating dipeptidyl peptidase 4 (mDPP4) in HRD and HRP mouse models. Correlation of hDPP4 immunohistochemistry staining with survival in 208 high-grade serous ovarian cancer patients.

Results

In our study, olaparib induced the chemokines mCCL5 and mCXCL10 in a dose-

SUBMITTER: Stange C 

PROVIDER: S-EPMC12356936 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature